Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
3.430
+0.070 (2.08%)
At close: Mar 17, 2026, 4:00 PM EDT
3.380
-0.050 (-1.46%)
After-hours: Mar 17, 2026, 6:15 PM EDT
Prelude Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts that cover Prelude Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $4.67, which forecasts a 36.15% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $6.00.
Price Target: $4.67 (+36.15%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Prelude Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $3 → $6 | Buy | Maintains | $3 → $6 | +74.93% | Mar 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +45.77% | Sep 23, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $4 → $3 | Buy | Maintains | $4 → $3 | -12.54% | Aug 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +45.77% | May 5, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $4 | Buy | Reiterates | $4 | +16.62% | Apr 29, 2025 |
Financial Forecast
Revenue This Year
51.00M
from 12.14M
Increased by 320.10%
Revenue Next Year
102.00M
from 51.00M
Increased by 100.00%
EPS This Year
-1.07
from -1.29
EPS Next Year
-0.44
from -1.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 105.0M | 105.0M | |||
| Avg | 51.0M | 102.0M | |||
| Low | n/a | 98.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 764.9% | 105.9% | |||
| Avg | 320.1% | 100.0% | |||
| Low | - | 92.2% |
EPS Forecast
| EPS | 2026 | 2027 |
|---|---|---|
| High | -1.10 | 0.12 |
| Avg | -1.07 | -0.44 |
| Low | -1.03 | -0.96 |
EPS Growth
| EPS Growth | 2026 | 2027 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.